Swedish biotechnology research company Tripep AB has achieved additional positive results in pre-clinical trials of its investigational hepatitis C vaccine, ChronVac-C DNA, combined with a DNA delivery system developed by Inovio Biomedical Corporation.
Subscribe to our email newsletter
Ongoing toxicity studies of ChronVac-C delivered using Inovio’s electroporation-based system revealed that the combination induces a humoral response in rabbits that is comparable to results previously observed in mice.
“These results provide encouragement that the combination of ChronVac-C with the MedPulser DNA delivery system may work well in humans and indicate that our collaboration with Inovio is progressing very well,” said Tripep’s CEO, Jan Nilsson.
Hepatitis is a disease characterized by inflammation of the liver. Hepatitis C virus (HCV) is spread primarily by direct contact with human blood, the major causes worldwide being the use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized.